Human evidence record · Levocarnitine / L-carnitine

Levocarnitine improves cardiac function in hemodialysis patients with left ventricular hypertrophy

Ejection fraction improved in the levocarnitine group versus control in the analyzed cohort.

Quick read

Human evidence record

What this study tells us

This was an early human study designed mainly to measure exposure, tolerability or a preliminary signal. Without stronger blinded controls, it should not be treated as definitive proof of benefit.

Who was studied?

Maintenance-hemodialysis patients with carnitine deficiency

How many?

n=222 randomized; 148 analyzed

What happened?

Ejection fraction improved in the levocarnitine group versus control in the analyzed cohort.

What stops us overclaiming?

Open-label design and attrition; not evidence for performance enhancement or fat loss in healthy users.

Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →

Key result

Ejection fraction improved in the levocarnitine group versus control in the analyzed cohort.

Study details

Study designMulticenter prospective randomized controlled trial (open-label)

PopulationMaintenance-hemodialysis patients with carnitine deficiency

Sample size222 randomized; 148 analyzed

RouteOral

Regimen / exposure20 mg/kg/day levocarnitine

Duration12 months

ComparatorNo levocarnitine

Primary endpoint / questionChange in left-ventricular ejection fraction

Safety resultDisease-specific clinical population; safety interpretation is tied to monitored dialysis care.

Key limitationsOpen-label design and attrition; not evidence for performance enhancement or fat loss in healthy users.

Registry / identifierPMID 26508680

Open Levocarnitine / L-carnitine page →Open primary source →